hBD-1 vs BI 456906
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | hBD-1 | BI 456906 |
|---|---|---|
| Category | Dental & Oral | Weight Management |
| Full Name | Human beta-defensin 1 | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 4490 Da | N/A |
| Half-Life | minutes to hours | Approximately 1 week |
| Amino Acids | 36 | N/A |
| Typical Dose | 1-10 µg/mL in experimental studies | Trial-dependent; weekly SC dosing |
| Route | Topical/Intraoral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 10 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.